PALO ALTO, Calif. & SYDNEY, Australia, Apr 18, 2005 (BUSINESS WIRE) -- Agilent Technologies Inc. (NYSE:A) and Proteome
Systems, a leading international proteomics company, today announced
they have signed a marketing agreement to collaborate on an integrated
solution for the analysis of glycoproteins, molecules that are
important in the study of many diseases, including cancer, influenza
and arthritis. Under the agreement, Proteome Systems will make its
GlycomIQ software, a comprehensive platform for the mass spectrometric
analysis of protein-associated glycans (polysaccharides), compatible
with the Agilent XCT, XCT Plus and XCT Ultra ion trap mass
spectrometers.
Proteome Systems developed GlycomIQ to address the emerging field
of glycomics, which examines how glycosylation, or the addition of
sugars to proteins, affects biological processes and systems. GlycomIQ
comprises kits, consumables and informatics software developed
specifically for automated glycan analysis.
"Analysis of protein glycosylation is a demanding task that has
often been reserved for specialized laboratories," said Nicolle
Packer, executive vice president and head of glycoproteomics of
Proteome Systems. "The combination of Agilent's robust, sensitive MS
technology with our cutting-edge, automated glycomics system creates a
powerful integrated solution that will streamline the study of
glycoproteins."
The co-marketed product is expected to be available this summer.
Agilent and Proteome Systems will also collaborate on the development
of applications and seminars as part of the marketing agreement.
"Agilent is proud of this collaboration with Proteome Systems,"
said Taia Ergueta, general manager of Agilent's Proteomics and LC/MS
business. "It illustrates our ongoing commitment to making
leading-edge life science research accessible to more scientists and
more laboratories. Using Agilent's protein separation and LC/MS
products and Proteome Systems' GlycomIQ software, life scientists will
be better able to produce, analyze and integrate complex data on the
forefront of proteomics research."
About Proteome Systems
Proteome Systems' Technology business develops and commercializes
innovative technology solutions to enable proteomics and glycomics
research. These solutions include integrated instrument-based systems,
consumables and bioinformatic software. Proteome Systems' Discovery &
Diagnostics business discovers protein biomarkers that have potential
for use as diagnostics and therapeutic targets in the areas of
respiratory disease, neurobiology and aging and cancer. Additional
information about Proteome Systems can be found at
www.proteomesystems.com.
About Agilent Integrated Biology Solutions
Agilent Technologies is a leading supplier of life science
research systems that enable scientists to understand complex
biological processes, determine disease mechanisms and speed drug
discovery. Engineered for sensitivity, reproducibility and workflow
productivity, Agilent's integrated biology solutions include
instrumentation, microfluidics, software, microarrays, consumables and
services for genomics, proteomics and metabolomics applications.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a global technology leader
in communications, electronics, life sciences and chemical analysis.
The company's 28,000 employees serve customers in more than 110
countries. Agilent had net revenue of $7.2 billion in fiscal year
2004. Information about Agilent is available on the Web at
www.agilent.com.
NOTE TO EDITORS: Press releases, photography and other information
can be accessed on the Agilent Life Sciences and Chemical Analysis
newsroom at www.agilent.com/about/newsroom/lsca.
Further technology, corporate citizenship and executive news is
available on the Agilent news site at www.agilent.com/go/news.
SOURCE: Agilent Technologies Inc.
Weber Shandwick, for Agilent
Frank Orrico, 312-397-6632
forrico@webershandwick.com
or
Buchan Communications, for Proteome Systems
Rebecca Christie, + 61 2 9237 2800
rchristie@bcg.com.au